Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/126352
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAsó, Ester-
dc.contributor.authorFerrer, Isidro (Ferrer Abizanda)-
dc.date.accessioned2018-11-22T14:01:32Z-
dc.date.available2018-11-22T14:01:32Z-
dc.date.issued2014-03-05-
dc.identifier.urihttp://hdl.handle.net/2445/126352-
dc.description.abstractThe limited effectiveness of current therapies against Alzheimer's disease (AD) highlights the need for intensifying research efforts devoted to developing new agents for preventing or retarding the disease process. During the last few years, targeting the endogenous cannabinoid system has emerged as a potential therapeutic approach to treat Alzheimer. The endocannabinoid system is composed by a number of cannabinoid receptors, including the well-characterized CBI and CB2 receptors, with their endogenous ligands and the enzymes related to the synthesis and degradation of these endocannabinoid compounds. Several findings indicate that the activation of both CBI and CB2 receptors by natural or synthetic agonists, at non-psychoactive doses, have beneficial effects in Alzheimer experimental models by reducing the harmful beta-amyloid peptide action and tau phosphorylation, as well as by promoting the brain's intrinsic repair mechanisms. Moreover, endocannabinoid signaling has been demonstrated to modulate numerous concomitant pathological processes, including neuroinflammation, excitotoxicity, mitochondrial dysfunction, and oxidative stress. The present paper summarizes the main experimental studies demonstrating the polyvalent properties of cannabinoid compounds for the treatment of AD, which together encourage progress toward a clinical trial.-
dc.format.extent11 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherFrontiers Media-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3389/fphar.2014.00037-
dc.relation.ispartofFrontiers in Pharmacology, 2014, vol. 5-
dc.relation.urihttps://doi.org/10.3389/fphar.2014.00037-
dc.rightscc by (c) Aso, Ester; Ferrer, Isidro (Ferrer Abizanda), 2014-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subject.classificationMalaltia d'Alzheimer-
dc.subject.classificationCànnabis-
dc.subject.otherAlzheimer's disease-
dc.subject.otherCannabis-
dc.titleCannabinoids for treatment of Alzheimer’s disease: moving toward the clinic-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.date.updated2018-07-24T12:41:31Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Articles publicats en revistes (Patologia i Terapèutica Experimental)

Files in This Item:
File Description SizeFormat 
AsoE.pdf810.16 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons